About this book
Every 5 seconds someone somewhere is diagnosed with diabetes, and every 10 seconds someone dies of it. Even worse, worldwide incidence rates still inexorably escalate. Thus, it is pressing to envisage the extent of the diabetes problem and ensure synergistic approaches aiming in alleviation of its ghastly toll. The chapters of this book report cutting-edge research on molecular events in adiposity and type 2 diabetes, thus opening the way for innovative drug-based therapeutic strategies. It addresses all those who wish to keep in touch with recent developments in the field.
Content Level » Research
Keywords » antidiabetic therapy - diabetes - insulin resistance - obesity - ß-cell
Related subjects » Cell Biology - Human Physiology - Internal Medicine - Molecular Medicine - Pharmaceutical Science
Table of contents
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes. Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects